Table 2.
Multivariate Analysis of Risk Factors for Increased microparticles
| Risk factors | β | 95% CI | P |
|---|---|---|---|
| (A) Risk factors for increased CD31+CD42−EMP | |||
| Age | 0.055 | –0.90–1.71 | 0.539 |
| Male sex | 0.006 | –31.30–33.83 | 0.937 |
| ESRD | 0.766 | 122.69–241.12 | <0.001 |
| DM | –0.111 | –60.55–13.23 | 0.206 |
| HTN | 0.298 | 16.33–110.11 | 0.009 |
| Use of antiplatelet agent | 0.179 | 0.82–77.05 | 0.054 |
| (B) Risk factors for increased CD51+EMP | |||
| Age | 0.094 | –0.16–0.37 | 0.422 |
| Male sex | –0.172 | –12.12–1.05 | 0.098 |
| ESRD | 0.157 | –6.14–17.31 | 0.347 |
| DM | 0.032 | –6.92–9.02 | 0.794 |
| HTN | 0.053 | –7.89–11.33 | 0.723 |
| Use of antiplatelet agent | 0.172 | –2.39–14.09 | 0.164 |
| (C) Risk factors for increased CD31+CD42+PMP | |||
| Age | 0.052 | –1.46–2.37 | 0.640 |
| Male sex | 0.080 | –28.02–67.50 | 0.414 |
| ESRD | 0.225 | 2.13–129.50 | 0.041 |
| DM | 0.007 | –52.34–55.97 | 0.947 |
| HTN | –0.024 | –74.93–62.75 | 0.861 |
| Use of antiplatelet agent | 0.230 | 3.21–115.13 | 0.038 |
CI, confidence interval; EMP, endothelial microparticle; ESRD, end-stage renal disease; DM, diabetes mellitus; HTN, hypertension; PMP, platelet-derived microparticle.